Oxford Cannabinoid Technologies first dosing a "major achievement" - Proactive Research Analyst
London, UK
|
July 27, 2023 10:38 AM Eastern Daylight Time
Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on Oxford Cannabinoid Technology Holdings PLC. The pharmaceutical group announced on 27 July that it has commenced its phase I clinical trial for lead drug candidate, OCT461201, marking the administration of the first human dose. Appiah describes the news as a "major achievement" for Oxford Cannabinoid Technologies, highlighting its transformation from a development company into being a clinical company He also gives an overview of other recent news from the business. For more details, read Daniel's full report by clicking the link provided.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
